Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335873 | 0.86 | PARG (0.47) | RORCPARGKMT2AHPGDMAPT | |
| SCHEMBL17335990 | 0.81 | SMN1; SMN2 (0.50) | PARGKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL17335989 | 0.79 | PARG (0.41) | RORCPARGRXFP1KMT2AKDM4E | |
| SCHEMBL19322789 | 0.78 | RORC (0.56) | RORCPARGRXFP1KDM4EALDH1A1 | |
| SCHEMBL14927474 | 0.76 | RORA (0.45) | RORCPARGKMT2A | |
| SCHEMBL10084682 | 0.72 | PARG (0.44) | RORCPARGKDM4EALDH1A1HPGD | |
| SCHEMBL17434122 | 0.70 | RORC (0.52) | RORCNPY5RKMT2AKDM4EALDH1A1 | |
| SCHEMBL17434295 | 0.70 | RORC (0.61) | RORCNPY5RKMT2AKDM4EALDH1A1 | |
| SCHEMBL17433946 | 0.70 | RORC (0.51) | RORCPARGNPY5RKMT2AKDM4E | |
| SCHEMBL17433948 | 0.70 | RORC (0.51) | RORCPARGNPY5RKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | RORC 232/4885PARG 4791/4885NPY5R 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.